The Medical Letter on Drugs and Therapeutics
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Edoxaban (Savaysa) - The Fourth New Oral Anticoagulant

The FDA has approved edoxaban (Savaysa – Daiichi Sankyo), a once-daily, oral, direct factor Xa inhibitor, for treatment of venous thromoboembolism (VTE) and for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is the fourth new oral anticoagulant to be approved for VTE and nonvalvular atrial fibrillation.

STANDARD TREATMENT — Acute VTE (deep vein thrombosis or pulmonary embolism) is usually treated initially with a parenteral anticoagulant such as unfractionated heparin, low molecular weight heparin (LMWH), or fondaparinux (Arixtra, and generics). Warfarin (Coumadin, and others) is started on the same day as parenteral therapy and titrated to an INR of 2-3. After ≥5 days, the parenteral anticoagulant is stopped and warfarin is continued as monotherapy. The new oral anticoagulants dabigatran etexilate (Pradaxa), ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1465
 Downloadable, electronic issue - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian